Today: 9 April 2026
Subscribe
Browse Category

NASDAQ:AXON 15 October 2025 - 26 February 2026

Dow Jones today: DJIA rises 300 points with Nvidia earnings in the crosshairs

Dow Jones today: DJIA rises 300 points with Nvidia earnings in the crosshairs

The Dow rose 307.8 points to 49,482.3 in early afternoon trading Wednesday. Investors awaited Nvidia’s quarterly report, with options markets pricing a 5.6% post-earnings move, the smallest in three years. IBM climbed over 4%, while Axon Enterprise jumped on strong earnings. GoDaddy and Lowe’s fell after weak forecasts.
25 February 2026
···········
Axon stock price jumps 22% as strong results fuel AI-led growth hopes; next catalyst in April

Axon stock price jumps 22% as strong results fuel AI-led growth hopes; next catalyst in April

Axon shares jumped 22% to $540.04 after reporting a 46% surge in 2025 bookings to $7.4 billion and forecasting 2026 revenue growth of up to 30%. The company split its reporting to highlight AI-driven software and services apart from hardware. Non-GAAP profit rose, but net income remained thin due to higher spending. Axon’s stock trades at about 57 times forward earnings, above the industry median.
25 February 2026
··
AppLovin stock price rises in midday trade as Needham turns bullish on Axon e-commerce push

AppLovin stock price rises in midday trade as Needham turns bullish on Axon e-commerce push

AppLovin shares rose 1.2% to $550.25 midday Wednesday after Needham upgraded the stock to “buy” and set a $700 target, citing gains in e-commerce ad revenue and new retail clients. Investors await the company’s Feb. 11 earnings report for more detail on Axon’s performance and advertiser growth. The SEC continues to investigate AppLovin’s data practices.
28 January 2026
···
AppLovin stock rises after Feb. 11 earnings date set as Axon checks drive focus

AppLovin stock rises after Feb. 11 earnings date set as Axon checks drive focus

AppLovin shares rose about 2.5% to $632.92 in after-hours trading Wednesday after the company announced it will report fourth-quarter and full-year 2025 results on Feb. 11, following the U.S. market close. The stock traded between $611 and $643 during the session. CEO Adam Foroughi and CFO Matthew Stumpf will host a results webinar at 5 p.m. ET that day.
8 January 2026
···
Axon Enterprise (AXON) Stock: Latest News, Analyst Forecasts, and Key Catalysts as of December 20, 2025

Axon Enterprise (AXON) Stock: Latest News, Analyst Forecasts, and Key Catalysts as of December 20, 2025

Axon Enterprise shares closed at $594.20 on Dec. 19, up 5.4% after announcing early redemption of its 0.50% convertible notes due 2027. The company notified holders they may convert notes until Feb. 6, 2026, with settlement set for Feb. 10. Recent headlines also include new municipal AI-policing contracts and an analyst price-target cut that kept a bullish rating.
20 December 2025
·
Axon Enterprise (AXON) Stock Forecast: Tariff Hit, AI Ambitions and Wall Street’s 40% Upside View – December 11, 2025

Axon Enterprise (AXON) Stock Forecast: Tariff Hit, AI Ambitions and Wall Street’s 40% Upside View – December 11, 2025

Axon Enterprise shares closed at $568.39 on December 10, up 3.98% but still about 35–40% below their August peak near $886. The stock plunged after Q3 earnings, which showed 31% revenue growth but missed profit forecasts due to U.S. tariffs. Analysts’ 12-month price targets range from $815 to $845. Short selling has eased slightly as the stock stabilizes.
11 December 2025
·
Axon Stock (AXON) Today: Price, Forecasts and AI Policing Risks – December 7, 2025

Axon Stock (AXON) Today: Price, Forecasts and AI Policing Risks – December 7, 2025

Axon shares closed at $550.95 on December 6, 2025, down 38% from their August high of $885.92 and 31% over six months. The company, now valued at about $43 billion, faces scrutiny over its AI policing tools and a facial-recognition body-camera trial in Canada. Wall Street price targets average $800–815. Short interest remains modest at 2–3% of free float.
7 December 2025
··
Axon Enterprise (AXON) Stock Plunges on Earnings Miss – What’s Next for the Taser Maker?

Axon Enterprise (AXON) Stock Plunges on Earnings Miss – What’s Next for the Taser Maker?

Axon Enterprise shares plunged nearly 20% in early November 2025 after missing third-quarter profit estimates, dropping from $706 to the mid-$560s. The company raised its full-year revenue forecast to $2.74 billion, citing 31% growth and strong demand for new products. Axon announced a $625 million acquisition of Carbyne to expand its public safety tech portfolio. The stock’s post-earnings drop erased its year-to-date gains.
5 November 2025
···
Axon Stock Rockets 420% Overseas as Wall Street Targets $1,000 – Should You Buy the Dip?

Axon Enterprise Rockets Past Revenue Goals – But EPS Miss Sends Stock Reeling

Axon reported Q3 2025 revenue of $711 million, up 31% year-over-year, led by 41% growth in Software & Services sales. The company posted a GAAP net loss of $2 million but non-GAAP net income of $98 million. Shares dropped about 14% after earnings, trading near $608, though the market cap remains around $56.9 billion. Management raised full-year revenue guidance to approximately $2.74 billion.
4 November 2025
··
Axon Stock Rockets 420% Overseas as Wall Street Targets $1,000 – Should You Buy the Dip?

Axon Stock Rockets 420% Overseas as Wall Street Targets $1,000 – Should You Buy the Dip?

Axon Enterprise shares spiked 420.8% in thin London trading this week, then rebounded in the U.S. to $701 after a recent 8.5% drop. Q2 revenue rose 32.6% to $668.5 million, beating estimates. The company announced an $800 million deal to acquire AI 911 firm Prepared and unveiled new AI products. Arizona approved a $1.3 billion headquarters campus for Axon.
23 October 2025
··
AI Stock Frenzy: Growth Stocks Go Parabolic as Tech Rally Surges

AI Stock Frenzy: Growth Stocks Go Parabolic as Tech Rally Surges

The Nasdaq hit about 22,680 and the S&P 500 hovered near 6,664 as investors poured into AI-driven growth stocks. Nvidia surged nearly 60% year-over-year, while AMD almost doubled in 2025 after major AI chip deals. CrowdStrike traded near record highs, up 56% annually. Analysts remain bullish, but some warn valuations are stretched.
20 October 2025
·········
Axon Stock Soars as AI Tech and Big Deals Fuel Rally – Key Facts Inside

Axon Stock Soars as AI Tech and Big Deals Fuel Rally – Key Facts Inside

Axon closed at about $705 on Oct. 14, 2025, up 20% year-to-date but 17% below its 52-week high. Q2 earnings beat expectations at $2.12 per share on $668.5 million revenue. The company announced the acquisition of Prepared and launched a new AI body camera. Arizona approved a $1.3 billion HQ campus, but Scottsdale’s City Council plans a legal challenge.
15 October 2025
···

Stock Market Today

  • Avalyn Pharma Plans IPO to Fund Phase 3 Trials of Inhaled Respiratory Drugs
    April 9, 2026, 4:45 AM EDT. Avalyn Pharma, a Cambridge-based biotech, aims to raise funds through an IPO to advance inhaled formulations of approved lung drugs into phase 3 trials. The lead candidate, AP01, an inhaled form of pirfenidone for progressive pulmonary fibrosis, is in phase 2b. The company also pursues AP02, inhaled nintedanib, and plans preclinical work on AP03, a combination therapy. Avalyn has previously raised over $310 million, including $100 million in 2025, and holds $138 million in cash. CEO Lyn Baranowski brings experience from AstraZeneca-related respiratory drug development. The IPO follows a rebounding biotech market early in 2026, with peers like SpyGlass and Veradermics also focusing on new formulations of approved drugs.

Latest article

Wall Street Feels the Heat (and Thrill): Fed Cuts, Tariffs & Mega-Mergers Set NYSE Buzz

US Stock Market Today: Live Updates 09.04.2026

9 April 2026
LIVEMarkets rolling coverageStarted: April 9, 2026, 12:00 AM EDTUpdated: April 9, 2026, 4:45 AM EDT Avalyn Pharma Plans IPO to Fund Phase 3 Trials of Inhaled Respiratory Drugs April 9, 2026, 4:45 AM EDT. Avalyn Pharma, a Cambridge-based biotech, aims to raise funds through an IPO to advance inhaled formulations of approved lung drugs into phase 3 trials. The lead candidate, AP01, an inhaled form of pirfenidone for progressive pulmonary fibrosis, is in phase 2b. The company also pursues AP02, inhaled nintedanib, and plans preclinical work on AP03, a combination therapy. Avalyn has previously raised over $310 million, including $100
Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

Why IREN Stock Is Back in Focus as AI Ambitions Meet Funding Fears

8 April 2026
IREN shares rose 1.8% to $35.74 Wednesday as investors assessed its $6 billion share program and shift from bitcoin mining to AI cloud services. The company’s revenue fell to $184.7 million last quarter, with a net loss of $155.4 million. IREN recently announced a five-year, $9.7 billion AI cloud deal with Microsoft. Options trading volume hit 103,000 contracts Tuesday, with sentiment described as mixed.
Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

Amazon Stock Could Jump 50% as Wall Street Reconsiders Its $200 Billion AI Bet

8 April 2026
Amazon closed at $213.77 Tuesday, with BNP Paribas maintaining a $320 price target, citing strong AI demand despite Amazon’s planned $200 billion capex for 2026. The company’s February forecast of higher spending sent shares down 11.5% after hours, even as AWS revenue rose 24% to $35.6 billion in the December quarter. Alphabet and Microsoft are also ramping up AI infrastructure spending.
Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

Sensex Soars 2,946 Points, Nifty Near 24,000 After Iran Ceasefire and RBI Pause

8 April 2026
The Sensex surged 2,946 points to 77,562.90 on Wednesday, its best day in five years, as a U.S.-Iran ceasefire and steady RBI rates pushed Indian markets higher. Brent crude fell 14.4% to $93.49 a barrel, easing pressure on the rupee, which rose 0.5% to 92.58 per dollar. All 16 major sectors gained, led by financials and auto stocks. The RBI kept its repo rate at 5.25% and forecast slower growth ahead.
Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

Netflix Stock Draws Fresh Institutional Buying Ahead of Earnings After Goldman Upgrade

8 April 2026
Stock Yards Bank & Trust Co. increased its Netflix stake by 1,141.9% to 29,074 shares in Q4, while Ethos Capital Management disclosed a new 19,610-share position worth $1.84 million. The moves come ahead of Netflix’s April 16 earnings report and follow a Goldman Sachs upgrade to Buy with a $120 target. Insiders Reed Hastings and Greg Peters sold shares earlier this year under preset trading plans. Netflix last traded at $98.82.
Go toTop